EBRC has been active in clinical trials for over 15 years and continues to be a site that has been involved in landmark studies involving the treatment of age-related macular degeneration, diabetic retinopathy and retinal vein occlusions. EBRC continues to dedicate our time and efforts toward promoting the advancement in retinal research and improving our surgical and medical care for each of our patients.
Our research team carefully evaluates each research study and selects well-designed and safe clinical studies that will not only benefit each of our participating patients, but also aid in the future discovery of treatment for retinal diseases.
Clinical Trials
Active Clinical Trials
Central Retinal or Hemiretinal Vein Occlusion
- Comino Study is a phase III trial. This Study will Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion(Genentech/Roche)
Symptomatic Epiretinal Membrane
- Protocol AM with the Diabetic Retinopathy Clinical Research Network. This Study is a Phase III trial Randomized Trial Comparing Immediate vs. Deferred Surgery for Symptomatic Epiretinal Membrane or ERM (DRCR Network)
Diabetic Macular Edema
- Pagoda Study is a Phase III trial This Study Will Evaluate the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System With Ranibizumab in Participants With Diabetic Macular Edema Compared With Intravitreal Ranibizumab (Genentech/Roche)
- Rhone X is a Phase III Trial. This Study Evaluates the Long-Term Safety and Tolerability of Faricimab in Participants With Diabetic Macular Edema (Genentech/Roche)
Completed Clinical Trials
Age-Related Macular Degeneration
- RE-VIEW: Phase IV, Aflibercept injections in subjects for the treatment of neovascular age-related macular degeneration.
- HARBOR: Phase III, Ranibizumab injections in subjects with subfoveal neovascular age related macular degeneration.
- DENALI: Phase IIIB, Verteporfin photodynamic therapy administered in conjunction with ranibizumab in subjects with choroidal neovascularization secondary to age-related macular degeneration.
- VIEW 1: Phase III, VEGF-Trap injections in subjects with neovascular age related macular degeneration.
- SAILOR: Phase IIIb, Ranibizumab injections in subjects with macular edema secondary to age-related macular degeneration.
- PIER: Phase IIIb, Ranibizumab injections with subfoveal choroidal neovascularization with or without classic CNV secondary to age-related macular degeneration.
- LUCERNE: A Study to Evaluate the Efficacy and Safety of Faricimabin Participants With Neovascular Age-Related Macular Degeneration. This study will evaluate the efficacy, safety, durability, and pharmacokinetics of Faricimab administered at intervals as specified in the protocol, compared with aflibercept once every 8 weeks (Q8W), in participants with neovascular age-related macular degeneration (nAMD).
- MERLIN: Study of Safety and Efficacy of Brolucizumab 6mg Dosed Every 4 Weeks Compared to Aflibercept 2mg Dosed Every 4 Weeks in Patients with Retinal Fluid Despite Frequent Anti-VEGF Injections.
- HAWK: Phase III, Efficacy and Safety of RTH258 Versus Aflibercept in the treatment of active choroidal neovascularization secondary to age-related macular
degeneration. - CHROMA: Phase III Lampalizumab injections in subjects for the treatment of geographic atrophy secondary to age-related macular degeneration.
- PROXIMA-A: An epidemiologic study seeking to better characterize relationships between visual function and the progression (worsening) of geographic atrophy due to age-related macular degeneration.
- OMASPECT: Open-label extension study evaluating the safety and tolerability of lampalizumab injections for geographic atrophy secondary to age-related macular degeneration.
- SEQUOIA: Safety and Efficacy of Abicipar Pegol in Patients with Neovascular Age-Related Macular Degeneration; Phase III aibicipar pegol injections in subjects for the treatment of neovascular age-related macular degeneration compared to ranibizumab.
- PANDA-1: Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular Age-related Macular Degeneration. The purpose of this clinical study is to evaluate the efficacy and safety of two different levels of conbercept intravitreal injection as compared to the approved vascular endothelial growth factor antagonist active control, aflibercept intravitreal injection, in subjects with neovascular AMD.
Diabetic Macular Edema
- VISTA: Phase III, VEGF-Trap injections/laser in subjects for the treatment of diabetic macular edema.
- IDEAL: Phase II, iCO-007 as monotherapy or in combination with Ranibizumab or laser for the treatment of diabetic macular edema.
- READ3: Phase III, Ranibizumab for the treatment of diabetic macular edema with high dose.
- RIDE: Phase III, Ranibizumab injections in subjects with clinically significant macular edema secondary to diabetes.
Diabetic Retinopathy
- Protocol W: Diabetic Retinopathy Clinical Research Network: Determine the efficacy and safety of aflibercept injections for prevention of proliferative diabetic retinopathy or center-involved diabetic macular edema and to compare long-term visual outcomes in eyes receiving anti-vascular endothelial growth factor therapy.
- Protocol AC: Diabetic Retinopathy Clinical Research Network: Aflibercept vs. Bevacizumab + Deferred Aflibercept for the Treatment of Center Involved Diabetic Macular Edema.
- Protocol AE: Diabetic Retinopathy Clinical Research Network: A Pilot Study EvaluatingPhotobiomodulation Therapy for Diabetic Macular Edema.
- PANORAMA: Phase III study assessing the efficacy of aflibercept injections compared to sham treatment in the improvement of moderately severe to severe nonproliferative diabetic retinopathy.
- YOSEMITE: A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema. This study will evaluate the efficacy, safety, and pharmacokinetics of Faricimab administered at 8-week intervals or as specified in the protocol following treatment initiation, compared with aflibercept once every weeks, in participants with diabetic macular edema.
Retinal Vein Occlusion
- COPERNICUS: Phase III, VEGF-Trap injections in subjects with macular edema secondary to central retinal vein occlusion.
- HORIZON: Phase III, Ranibizumab injections in subjects with macular edema secondary to branch retinal and central retinal vein occlusion.
- SCORE: Phase III, Ranibizumab injections in subjects with macular edema following either branch retinal vein occlusion, central retinal vein occlusion or hemi retinal vein occlusion.
- RAVEN: A Phase III Trial Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients with Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion.
- BRAVO: Phase III, Ranibizumab injections in subjects with macular edema secondary to branch retinal vein occlusion.
- CRUISE: Phase III, Ranibizumab injections in subjects with macular edema secondary to central retinal vein occlusion.
- SCORE2: Phase III Bevacizumab vs. Aflibercept in subjects for the treatment of central retinal vein occlusion.
- SAPPHIRE: Phase III study utilizing suprachoroidal injection of Triamcinolone Acetonide with Aflibercept in patients with macular edema following retinal vein occlusion.
Vitreomacular Traction
Complete Patient Forms
Download Form
